Market closedNon-fractional

ANI Pharmaceuticals/ANIP

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About ANI Pharmaceuticals

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Ticker

ANIP

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Baudette, United States

Employees

642

ANIP Metrics

BasicAdvanced
$1.2B
Market cap
38.73
P/E ratio
$1.62
EPS
0.81
Beta
-
Dividend rate
$1.2B
0.81
3.949
3
60.75
60.928
4.57%
1.52%
3.91%
8.71%
38.73
2.26
2.75
5.46
12.52
44.26%
-193.69%
34.38%
7.85%

What the Analysts think about ANIP

Analyst Ratings

Majority rating from 5 analysts.
Buy

ANIP Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
13.24% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$137M
4.41%
Net income
$18M
1,554.55%
Profit margin
13.24%
1,495.18%

ANIP Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 21.49%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.28
$1.27
$1.00
$1.21
-
Expected
$0.68
$0.84
$0.86
$1.00
$0.96
Surprise
88.93%
50.59%
16.96%
21.49%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ANI Pharmaceuticals stock?

ANI Pharmaceuticals (ANIP) has a market cap of $1.2B as of July 05, 2024.

What is the P/E ratio for ANI Pharmaceuticals stock?

The price to earnings (P/E) ratio for ANI Pharmaceuticals (ANIP) stock is 38.73 as of July 05, 2024.

Does ANI Pharmaceuticals stock pay dividends?

No, ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next ANI Pharmaceuticals dividend payment date?

ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders.

What is the beta indicator for ANI Pharmaceuticals?

ANI Pharmaceuticals (ANIP) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell ANI Pharmaceuticals stock

Buy or sell ANI Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing